GlassScriptPhysician profile
Vaneet K Sandhu
NPI 1134362163
$47,297.27
in general payments reported to CMS, 2019-2025
12 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,146 · 2020: $8,846 · 2021: $8,712 · 2022: $10K · 2023: $5,323 · 2024: $13K · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $2,452 · Travel and Lodging: $1,027 · Education: $93.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,950.00 |
| Food and Beverage | $2,451.55 |
| Travel and Lodging | $1,027.24 |
| Education | $93.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $36,147.92 | 2019-2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $6,754.08 | 2021-2023 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $2,181.28 | 2021-2023 | Saphnelo |
| Janssen Biotech, INC. | $749.93 | 2022-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $456.45 | 2022-2023 | Tavneos |
| Abbvie INC. | $278.23 | 2019-2023 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $227.66 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.04 | 2023 | |
| Ucb, INC. | $167.50 | 2022-2023 | Cimzia |
| Sanofi-Aventis U.S. LLC | $134.19 | 2021-2022 | |
| Novo Nordisk INC | $19.99 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaneet Sandhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.